Rigel Pharmaceuticals (RIGL) Accounts Payables (2010 - 2026)
Rigel Pharmaceuticals' quarterly Accounts Payables came in at $4.5 million in Q1 2026, up 13.45% year-on-year from $4.0 million in Q1 2025, and down 37.62% quarter-over-quarter from $7.2 million in Q4 2025.
Rigel Pharmaceuticals has reported Accounts Payables for 17 years, with the latest figure at $4.5 million in Q1 2026.
- For the quarter ending Q1 2026, Accounts Payables rose 13.45% year-over-year to $4.5 million; the trailing twelve-month figure through Mar 2026 stood at $4.5 million (up 13.45% YoY), and the FY2025 full-year result was $7.2 million, up 115.36% from the prior year.
- Accounts Payables for Q1 2026 stood at $4.5 million, down from $7.2 million in the prior quarter.
- The five-year high for Accounts Payables was $15.0 million in Q4 2022, with the low at $2.2 million in Q2 2022.
- Average Accounts Payables over 5 years is $5.9 million, with a median of $5.2 million recorded in 2023.
- Year-over-year, Accounts Payables soared 295.26% in 2022 and plunged 57.37% in 2025.
- Tracing RIGL's Accounts Payables over 5 years: stood at $15.0 million in 2022, then slumped by 52.39% to $7.1 million in 2023, then slumped by 53.25% to $3.3 million in 2024, then jumped by 115.36% to $7.2 million in 2025, then sank by 37.62% to $4.5 million in 2026.
- The last three Accounts Payables figures came in at $4.5 million (Q1 2026), $7.2 million (Q4 2025), and $3.8 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 1.05 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 83.00 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 10.62 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 8.64 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 489.30 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 1.03 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 126.63 Mn |
| 10 | Rigel Pharmaceuticals | 551.62 Mn | 404.94 Mn | 54.21 Mn | 4.49 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4.49 Mn |
| Dec 31, 2025 | 7.19 Mn |
| Sep 30, 2025 | 3.85 Mn |
| Jun 30, 2025 | 7.29 Mn |
| Mar 31, 2025 | 3.95 Mn |
| Dec 31, 2024 | 3.34 Mn |
| Sep 30, 2024 | 3.82 Mn |
| Jun 30, 2024 | 6.13 Mn |
| Mar 31, 2024 | 9.28 Mn |
| Dec 31, 2023 | 7.14 Mn |
| Sep 30, 2023 | 8.00 Mn |
| Jun 30, 2023 | 5.24 Mn |
| Mar 31, 2023 | 6.30 Mn |
| Dec 31, 2022 | 15.00 Mn |
| Sep 30, 2022 | 2.72 Mn |
| Jun 30, 2022 | 2.16 Mn |
| Mar 31, 2022 | 4.61 Mn |
| Dec 31, 2021 | 3.80 Mn |
| Sep 30, 2021 | 3.14 Mn |
| Jun 30, 2021 | 1.69 Mn |
| Mar 31, 2021 | 5.10 Mn |
| Dec 31, 2020 | 3.71 Mn |
| Sep 30, 2020 | 2.28 Mn |
| Jun 30, 2020 | 3.41 Mn |
| Mar 31, 2020 | 2.21 Mn |
| Dec 31, 2019 | 4.15 Mn |
| Sep 30, 2019 | 2.66 Mn |
| Jun 30, 2019 | 3.78 Mn |
| Mar 31, 2019 | 1.18 Mn |
| Dec 31, 2018 | 6.39 Mn |
| Sep 30, 2018 | 2.64 Mn |
| Jun 30, 2018 | 3.34 Mn |
| Mar 31, 2018 | 2.62 Mn |
| Dec 31, 2017 | 2.64 Mn |
| Sep 30, 2017 | 2.19 Mn |
| Jun 30, 2017 | 2.07 Mn |
| Mar 31, 2017 | 1.18 Mn |
| Dec 31, 2016 | 5.56 Mn |
| Sep 30, 2016 | 1.52 Mn |
| Jun 30, 2016 | 1.51 Mn |
| Mar 31, 2016 | 2.42 Mn |
| Dec 31, 2015 | 2.76 Mn |
| Sep 30, 2015 | 689,000.00 |
| Jun 30, 2015 | 1.10 Mn |
| Mar 31, 2015 | 1.14 Mn |
| Dec 31, 2014 | 1.61 Mn |
| Sep 30, 2014 | 1.02 Mn |
| Jun 30, 2014 | 1.90 Mn |
| Mar 31, 2014 | 1.16 Mn |
| Dec 31, 2013 | 3.90 Mn |
| Sep 30, 2013 | 1.03 Mn |
| Jun 30, 2013 | 2.12 Mn |
| Mar 31, 2013 | 2.14 Mn |
| Dec 31, 2012 | 1.70 Mn |
| Sep 30, 2012 | 1.39 Mn |
| Jun 30, 2012 | 1.91 Mn |
| Mar 31, 2012 | 1.92 Mn |
| Dec 31, 2011 | 1.56 Mn |
| Sep 30, 2011 | 1.28 Mn |
| Jun 30, 2011 | 1.46 Mn |
| Dec 31, 2010 | 1.40 Mn |